ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Medicalization of testosterone: reinventing the elixir of life
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Phil Goodman" data-source="post: 231722" data-attributes="member: 42777"><p>A few aspects of the TOM Trial should be highlighted. First, the participants in the TOM Trial had a high prevalence of cardiovascular risk factors at baseline; not an unexpected observation as the burden of comorbidities is high in mobility‐limited men. Indeed, nearly 25% of the participants had diabetes mellitus, half were obese, >80% had hypertension and approximately 50% of the participants had preexisting heart disease. Second, the starting dose of testosterone gel in the TOM Trial was higher than the dose at which treatment is initiated in clinical practice. However, the on‐treatment circulating mean serum testosterone levels in the TOM Trial were comparable to the levels seen in older men who participated in other trials;29 however, the majority of other studies enrolled “healthy” older men. Finally, the diversity of cardiovascular‐related events seen in the TOM Trial does not suggest a single mechanism; though the rapidity with which the events occurred suggests an acute mechanism. </p><p></p><p></p><p>[URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858095/pdf/AJA-20-131.pdf[/URL]</p></blockquote><p></p>
[QUOTE="Phil Goodman, post: 231722, member: 42777"] A few aspects of the TOM Trial should be highlighted. First, the participants in the TOM Trial had a high prevalence of cardiovascular risk factors at baseline; not an unexpected observation as the burden of comorbidities is high in mobility‐limited men. Indeed, nearly 25% of the participants had diabetes mellitus, half were obese, >80% had hypertension and approximately 50% of the participants had preexisting heart disease. Second, the starting dose of testosterone gel in the TOM Trial was higher than the dose at which treatment is initiated in clinical practice. However, the on‐treatment circulating mean serum testosterone levels in the TOM Trial were comparable to the levels seen in older men who participated in other trials;29 however, the majority of other studies enrolled “healthy” older men. Finally, the diversity of cardiovascular‐related events seen in the TOM Trial does not suggest a single mechanism; though the rapidity with which the events occurred suggests an acute mechanism. [URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858095/pdf/AJA-20-131.pdf[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Medicalization of testosterone: reinventing the elixir of life
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top